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Brain-derived exosomes from dementia
with Lewy bodies propagate α-synuclein
pathology
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Deborah Masliah1, Anthony Adame1, Eliezer Masliah1,2 and Robert A. Rissman1,3*
Abstract
Proteins implicated in neurodegenerative conditions such as Alzheimer’s disease (AD) and Dementia with Lewy
Bodies (DLB) have been identified in bodily fluids encased in extracellular vesicles called exosomes. Whether
exosomes found in DLB patients can transmit pathology is not clear. In this study, exosomes were successfully
harvested through ultracentrifugation from brain tissue from DLB and AD patients as well as non-diseased brain
tissue. Exosomes extracted from brains diagnosed with either AD or DLB contained aggregate-prone proteins.
Furthermore, injection of brain-derived exosomes from DLB patients into the brains of wild type mice induced
α-synuclein (α-syn) aggregation. As assessed through immunofluorescent double labeling, α-syn aggregation was
observed in MAP2+, Rab5+ neurons. Using a neuronal cell line, we also identified intracellular α-syn aggregation
mediated by exosomes is dependent on recipient cell endocytosis. Together, these data suggest that exosomes
from DLB patients are sufficient for seeding and propagating α-syn aggregation in vivo.
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Introduction
Misfolded protein aggregates are a pathological hallmark
of age-related neurodegenerative disorders such as Alz-
heimer’s disease (AD) and Dementia with Lewy Bodies
(DLB) [7, 26]. Termed proteinopathies, both disorders
result in synaptic dysfunction, neuron loss and cognitive
decline [2, 26]. AD pathology is classically defined as
plaques composed of amyloid beta (Aβ) and neurofibril-
lary tangles containing tau [13]. Likewise, Lewy Body
disorders such as DLB are characterized by clusters of
α-synuclein (α-syn) within the neuron cell body (called
“Lewy Bodies”) and terminals [36]. Yet the brains of pa-
tients clinically diagnosed with either disorder also con-
tain other aggregate formations. For example, Aβ
plaques are present in patients diagnosed with Lewy
Body disorders, with DLB plaque loads comparable to
AD [14, 20, 22, 44]. Conversely, patients with the
“plaque-only” variant of AD contain Lewy Bodies within
the neocortex and brainstem [13, 21]. Such heterogen-
eity between AD and DLB obfuscates proper treatment
and diagnosis.
Aβ, Tau and α-syn are thought to reconfigure into a
neurotoxic species that migrates into neighboring cells and
triggers protein aggregation [4]. Studies investigating
plaque initiation found Aβ plaques in animal brains intra-
cranially injected with AD patient brain homogenates [1,
37]. Neurofibrillary tangles and Lewy Bodies were also seen
in rodent brains injected with brains homogenates of tauo-
pathy and synucleinopathy patients, respectively [10, 24].
The seeding of exogenous misfolded proteins initiated the
aggregation of endogenous non-diseased protein, a charac-
teristic similar to prion proteins involved in spongiform en-
cephalopathy. In 2008, two separate studies reported α-
syn-positive deposits in human fetal dopaminergic neurons
grafted into Parkinson’s disease patients [25, 31]. Because
α-syn aggregation is not observed in midbrain neurons
until middle age [9], it was concluded that the implanted
neurons acquired α-syn pathology through host-to-graft
transmission. Subsequent studies in rodents and cell
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culture demonstrated neuron-to-neuron transfer of α-syn,
another characteristic thought to be exclusive to prion pro-
teins [12]. It is now accepted that Aβ, tau and α-syn
possess the ability to self-propagate and utilize cellular
connections to spread throughout the brain in a network-
specific manner as observed in human patients and rodent
models [4].
Although multiple methods of aggregate-prone protein
transmission have been proposed, such as the formation
of microtubes and membrane shedding, one attractive
mechanism of protein aggregate spread is through exo-
somes [3, 30, 42, 45]. Originating inside multivesicular
bodies (MVB) of the endocytic pathway, exosomes are
40–100 nm vesicles that are released into the extracellu-
lar space through the fusion of a MVB to the plasma
membrane [27]. Originally thought to serve as an alterna-
tive method of waste elimination, exosomes participate in
the transmission of various proteins and RNA between
cells [17]. Interestingly, α-syn, tau and amyloid precursor
protein (APP) are present within exosomes in vitro [11,
15, 41, 43, 53]. Exosomes harboring neurodegenerative-
associated proteins have been detected in blood, CSF and
urine of patients with neurodegenerative diseases [51].
Importantly, exosomes extracted from the plasma of MCI
and AD patients induced the formation of tau pathology
in non-diseased mice [53]. While CSF derived exosomes
from DLB patients have initiated α-syn aggregation in
vitro [47], it is unknown whether exosomes derived from
DLB patients exhibit similar pathogenicity in vivo.
The aims of this study were to 1) determine if the
protein content of brain-derived exosomes from patients
diagnosed with AD or DLB contain Aβ, tau and/or α-
syn over non-diseased individuals and 2) test the hy-
pothesis that brain derived exosomes from DLB patients
can seed and propagate α-syn pathology. Utilizing bio-
chemical techniques and animal models, we show that
brain exosome cargo isolated from AD and DLB brain
tissue contain Aβ and tau, with exosomes derived from
DLB brain tissue specifically containing α-syn. Further-
more, administering brain-derived exosomes into the
brains of non-diseased mice induced α-syn aggregates in
neurons, further bolstering the hypothesis that neurotoxic
proteins such as α-syn can be packaged into exosomes to
exacerbate synucleinopathy. Lastly, we demonstrate that α-
syn aggregation triggered by DLB exosomes is dependent
on endocytosis. These data further emphasize the role of
exosomes in propogating DLB pathology.
Materials and methods
Human samples
The demographics and diagnoses presented in Table 1
were obtained from patients neurologically and psycho-
metrically studied at the Alzheimer Disease Research
Center (ADRC) University of California, San Diego
(UCSD). All procedures were reviewed and approved by
the UCSD Institutional Review Board. Upon autopsy,
patient brains were collected by the UCSD ADRC
Neuropathology Core and sagittally divided at autopsy;
the left hemibrain was fixed in 10% buffered formalin
for neuropathological analysis and the right frozen at −70 °C
for subsequent exosome isolation.
Ultracentrifugation
Exosomes were isolated from frozen brain tissue
(Fig. 1a) as previously described [40]. Briefly, 0.5 g of
frozen frontal cortex was dissected and immersed in a solu-
tion of 20 units/ml of papain in Hibernate E (Life Tech-
nologies) (10:1 ratio) for 15 min at 37 °C. About 20 ml of
cold Hibernate E was added before homogenization. The
brain homogenate was passed through a 40 μl mesh filter
then fractionated though differential centrifugation: 300 g
for 10 min, 2000 g for 10 min, 10,000 g for 30 min. The
resulting supernatant was further clarified using a 0.2 μm
mesh filter and then centrifuged at 100,000 g for
70 min at 4 °C. The pellet was washed twice in 5 ml
PBS prior to centrifugation at 100,000 g for 80 min.
Both the supernatant (“control fraction”) and pellet
(“exosome fraction”) were collected for further analysis.
Antibodies towards CD63 (Systems Bioscience, Cat.
No: EXOAB-CD63A-1), CD81 (Systems Bioscience,
Cat. No: EXOAB-CD81A-1) and Alix (3A9, BioLegend,
Cat. No:634,501) were used to characterize each
fraction.
Mice
Rodent experiments abided with NIH recommendations
for good animal practice and all animal use procedures
were reviewed and approved by the UCSD Institutional
Animal Care and Use Committee. Male C57BL/
6 N × DBA/2 F1 mice, ~4 months old, were intracrani-
ally injected with exosomes derived from a DLB patient
(N = 6) or a non-diseased patient (N = 5). 4.4 μg (~2 μl
in volume) of the exosome fraction was sterotaxically
injected into hippocampus (−2.0 AP, +1.5 ML, −1.3
DV) [39]. Four weeks post injection, mice were anes-
thetized with chloral hydrate (Sigma, C8383) and trans-
cardially perfused with 0.9% saline. Brains were removed
and drop-fixed in phosphate-buffered 4% paraformalde-
hyde, pH 7.4, at 4 °C for 48 h for further analysis.
Immunohistochemistical analysis
Paraffin sections from 10% buffered formalin-fixed hu-
man neocortical, limbic system and subcortical material
were stained with hematoxylin and eosin, thioflavin S,
ubiquitin (Dako, Z0458) and α-syn (Millipore, AB5038P)
were used for routine neuropathological analysis that in-
cluded assessment of plaques, tangles, Lewy bodies and
Braak stage. Additional staining for Syn1 (BD Biosciences,
Ngolab et al. Acta Neuropathologica Communications  (2017) 5:46 Page 2 of 10
Cat. No: 620,787), phosphorylated α-syn at serine 129
(pSer129 α-syn, Abcam, Cat.No: ab51253), Aβ (4G8, Cov-
ance, Cat. No: SIG-39200; 6E10, Covance, Cat.No: SIG-
39320) and pTau396 (antibody PHF1, generous gift from
Dr. P. Davies) were performed to further characterize Aβ
and tangle protein composition. Mouse brains injected
with human brain-derived exosomes were serially sec-
tioned at 40 μm (Vibratome 2000, Leica, Wetzlar,
Germany). Free-floating sections relevant to the injection
site were incubated overnight at 4 °C with Syn1 antibody,
followed by biotinylated horse anti-mouse IgG (1:100;
Vector Laboratories, BA-1000), Avidin D-horseradish per-
oxidase (1:200; Vector Laboratories, A-2004), and
subsequent detection with diaminobenzidine (DAB,
Vector Laboratories, SK-4100). Sections were imaged
with a bright-field digital microscope (Olympus, Shinjuku,
Japan). Counts of Syn1, pSer129 α-syn, Aβ and PHF1
immunoreactivity were performed using Image J and
expressed as optical density. A total of four images
per group were captured, converted to gray scale,
processed for proper threshold and dynamic scale set
to determine optical density.
Immunofluorescent colocalization analysis
For the double labeling studies, 40 μm sections were
immunolabeled with the Syn1 antibody and either
Table 1 Summary of clinical and pathological characteristics of all donors
Diagnosis Age (years) Brain weight (g) Education (years) DRS Braak stage Plaques
(counts/0.1 mm2)
Tangles
(counts/0.01 mm2)
Amyloid
angiopathy
(score)
Lewy
bodies
(score)
Ctl (N = 3) 82.33 ± 5 1142 ± 111 14 ± 3.4 140 ± 1 0 4.67 ± 0.67 0 0 0
AD (N = 3) 81.3 ± 4.7 1100 ± 156 12 ± 0 72.7 ± 8.3 6.2 ± 0 47.3 ± 4.6 6.7 ± 4.2 3 0
DLB (N = 3) 77 ± 13.9 1237 ± 9.7 14.7 ± 3.1 104 ± 11 4.2 ± 2.8 33 ± 1 2 ± 1 0.7 ± 0.2 3
Values reported in table are expressed as arithmetic mean ± standard mean of error (SEM)
Abbreviations: AD Alzheimer’s Disease, Ctl Control, DBL Dementia with Lewy Bodies, DRS Mattis Dementia Rating Scale
Fig. 1 Isolation of exosomes from patient brain tissue. a Schematic of ultracentrifugation protocol used to isolate exosomes from tissue. Note that the
pellet is the “exosome fraction”, and the supernatant is the “control fraction”. b Exosome identification markers present in the exosome fraction of Ctl,
AD and DLB brain tissue. c Top Row: Representative EM micrographs from control fraction as well as Ctl, AD and DLB exosome fractions. Bottom Row:
EM micrographs from control fraction and Ctl, AD and DLB exosome fractions stained with immunogold labeled anti-CD 63. Scale bar = 50 nm
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MAP2 (Clone 2B, Millipore, Cat. No: MAB378), Rab5
(15/Rab5, BD Biosciences, Cat. No: 610,281), GFAP
(Millipore, Cat. No: MAB3402) or a mouse specific α-
syn antibody (a generous gift from V.M-Y. Lee). Human
α-syn immunoreactivity was detected with a FITC-
tagged secondary antibody (Vector), while the other
antibodies were visualized with the Tyramide Signal
Amplification™-Direct (Red) system (Perkin Elmer). All
sections were processed simultaneously under the same
conditions, and experiments were performed in dupli-
cate in order to assess the reproducibility of results. All
fluorescent imaging studies were done on a DMI 4000B
inverted fluorescent microscope (Leica, Germany) with
an attached TCS SPE confocal system (Leica), using a
Leica 63X (N.A. 1.3) objective. A total of four optically
paired micrographs were analyzed with ImageJ colocali-
zation color map plugin to determine the percent of
human α-syn positive clusters within Rab5, MAP2, and
GFAP expressing cells. Efficacy of of α-syn cross-seeding
was reported as percent mouse α-syn clusters detected
within human α-syn positive cells.
Western blot
Protein content from exosome and control fractions was
separated on 4–12% Bis-Tris gels (Life Technologies,
NP0322BOX) then transferred to a polyvinylidene fluoride
(PVDF) membrane (Immobilon-P, Millipore, IPFL00010).
The membrane was blocked in 1% w/v BSA in PBS with
0.1% Tween 20 (PBS-T) for 1 h at room temperature,
followed by overnight incubation in primary antibody at
4 °C. Primary antibodies listed in the immunohistochemis-
try section above to were used to characterize exosome
protein cargo. After washing with PBS-T, the membrane
was incubated in the dark with HRP-conjugated secondary
antibodies specific to the primary antibody host for 1 h at
room temperature. Protein bands were detected using
Pierce ECL Plus Western Blotting substrate (Thermo
Scientific, 32,134) through a BioRad Molecular Imager
ChemiDoc (BioRad, Hercules, CA).
Transmission electron microscopy
To characterize exosomes, pellets fraction were fixed in
the ultracentrifugation tube with 4% PFA for 30–60 min
at room temperature. Pellet post-fixation was performed
with 1% OsO4 for 30 min and then rinsed with distilled
water. Following graded ethanol dehydration, the pellet
was block-stained with 1% uranyl acetate in 50% ethanol
for 30 min. The pellet was embedded in Taab 812 (Taab;
Aldermaston, UK) and polymerized for 12 h at 60 °C.
50–60 nm ultrathin sections were cut using a Leica
UCT ultramicrotome (Leica Microsystems, UK) and ex-
amined using a Hitachi 7100 transmission electron
microscope (Hitachi Ltd., Japan). Electron micrographs
were taken by a Veleta 2 k × 2 k MegaPixel side-
mounted TEM CCD camera (Leica Microsystems). Con-
trast/brightness of electron micrographs was edited
using Adobe Photoshop CS3.
To visualize the presence of α-syn within intact exo-
somes, fixed exosome pellets were blocked with exo-
some FSGB buffer (5% FSGB, 5% BSA in 50 mM Tris/
HCl pH 7.4) and incubated with Syn1 or CD63 (1:100
diluted in 1% FSGB and 1% BSA in PBS) overnight at 4 °
C. After washing, pellets were incubated with secondary
antibody (goat anti mouse IgG 6 nm gold particles 1:80,
AURION 806.022 diluted in 0.2% BSA in PBS) for 2 h.
Exosome pellets were washed with 0.2% BSA in PBS and
then with PBS alone. After post-fixation in 1% glutaral-
dehyde for 10 min, the pellets were washed 2 times with
distilled water and processed for visualization as de-
scribed above.
Cell culture
The B103 rat neuroblastoma cell line was used to
visualize exosome-mediated α-syn uptake due to previ-
ous observations of α-syn overexpression triggering ex-
cessive intracellular oligomeric α-syn accumulation and
neurite growth reduction [50]. Cells were seeded at
5 × 104 cells per well on poly-L-lysine coated glass cov-
erslips contained in a 12-well plate 24 h prior to exo-
some incubation. Endosomal inhibition was performed
either by incubating cells in 4 °C for 30 min or treating
with 80 μm Dynasore, a dynamin GTPase inhibitor, dis-
solved in DMSO for 30 min at 37 °C.
Statistical analysis
All microscopic quantifications were performed blind-
coded with four fields per slide evaluated per group. All
values in the figures are expressed as arithmetic
mean ± standard mean of error (SEM). Differences in
optical density and percent colocalization between Ctl
and DLB groups were analyzed using the two-tailed un-
paired Student’s t-test. Statistical analyses were calcu-
lated using Prism (GraphPad Software).
Results
Cohort clinicopathological data
Table 1 summarizes the clinical and pathological data of
each cohort. Tissue samples were from age-matched
non-diagnosed (Ctl) as well as AD or DLB individuals
(N = 3/cohort). There were no significant differences in
age or brain weight between groups. Patients diagnosed
with either AD or DLB scored below Ctl individuals in
the Mattis Dementia Rating Scale (DRS) (Ctl: 140 ± 1,
AD: 72.7 ± 8.3, DLB: 104 ± 11), a test used to determine
cognitive decline [35]. Each cohort received at least
12 years of education, as number of years of education
has shown to impact DRS performance (Ctl: 14 years
±3.4, AD: 12 years ±0, DLB: 14.7 years ±3.1) [8]. The
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AD and DLB brain tissues were scored in the later Braak
stages (AD: 6.2 ± 0, DLB: 4.2 ± 2.8), while Ctl tissue did
not exhibit any prominent Braak stage characteristics
(Ctl:0). Plaque density was greater in AD and DLB pa-
tient tissue compared to Ctl tissue (Ctl: 4.67 ± 0.67, AD:
47.3 ± 4.6, DLB: 33 ± 10). Similarly, neurofibrillary tangle
density was higher in AD and DLB patient tissue relative to
Ctl tissue (Ctl: 0, AD: 6.7 ± 4.2, DLB: 2 ± 1). Aβ angio-
pathology was prevalent in patient brains from AD patients
(Ctl: 0, AD: 3 ± 0, DLB: 0.7 ± 0.2) while Lewy Bodies were
found exclusively in DLB brain tissue (Ctl: 0, AD:0, DLB:
3 ± 0).
Exosomes isolated from brain tissue
Brain tissue from each cohort detailed in Table 1 was
processed via ultracentrifugation to isolate brain-derived
exosomes (Fig. 1a). The resulting pellets (“Exosome frac-
tion”) and supernatant (“Control fraction”) from each
cohort were analyzed by Western blot for tetraspanins
CD63 and CD81 as well as the cytosolic protein Alix.
These proteins are enriched in exosomal populations
and are used to identify exosomes [32]. Exosome frac-
tions of all cohorts expressed abundant amount of
CD63, CD81 and Alix compared to Control fractions
(Fig. 1b). TEM identified the presence of small vesicles
in the exosome but not control fraction of all cohorts
(Fig. 1c). Furthermore, immunogold staining for CD63
was present within the small vesicles in every exosomal
fraction (Fig. 1c). These data verify that exosomes were
successfully extracted from frozen brain tissue of healthy
individuals as well as AD and DLB patients.
Exosome cargo reflects brain pathology
We then assessed the cargo of brain-derived exo-
somes for aggregation-prone proteins. To further
characterize the protein aggregates identified in Table 1,
brain tissue from each cohort was analyzed for Aβ, tau
and α-syn through immunohistochemical staining
(Fig. 2a). Ctl tissue was negative for Aβ, tau and α-syn
staining. AD tissue exhibited strong α-syn-positive
clusters, Aβ plaques and dense p-Tau positive cell
bodies. Brain tissue from DLB patients contained
large α-syn positive intracellular deposits, indicative of
LB formation, as well as positive Aβ staining. West-
ern blot analysis revealed prominent signal for α-syn
specifically in the DLB exosome fraction (Fig. 2b),
while Aβ and p-Tau was present in both the AD and
DLB exosome fraction (Fig. 2c-d). In summary,
disease-associated proteins present in AD and DLB
brain tissue were identified in their respective exosome
fraction, consistent with previous studies assessing
exosome content isolated from transgenic rodent
brain tissue [40, 41].
Brain derived exosomes from DLB patient facilitates α-syn
accumulation
Previous studies have detected tau accumulation in
mouse brain tissue upon intracranial injection of cere-
bral spinal fluid (CSF) exosomes derived from AD pa-
tients [53]. Could exosomes derived from DLB brain
tissue exhibit similar properties and transmit DLB path-
ology to non-diseased tissue? To address this question,
we injected exosome fractions extracted from Ctl and
DLB human brain tissue into the cerebrum of non-
diseased mice (Fig. 3b). TEM immunogold labeling de-
tected visible α-syn clusters within exosomes from the
DLB exosomal fraction (Fig. 3a). DLB-injected mouse
brains exhibited significant intracellular and dendritic α-
syn immunostaining around the injection site compared
to Ctl-injected mouse brains (Fig. 3c, arrowheads, Fig.
3e). Higher levels of phosphorylated α-syn (pSer129 α-
syn) staining were observed in DLB-injected brain tissue
compared to Ctl-injected tissue (Fig. 3d, e). A significant
amount of phosphorylated tau staining around the cell
membrane was detected in DLB-injected tissue com-
pared to Ctl-injected tissue; however, Aβ expression was
low in both DLB and Ctl-injected groups (Fig. 3d, e).
Accumulation of α-syn occurs in neurons and astrocytes
Next, we sought to further characterize the mechanisms
DLB-derived exosomes utilize to potentially trigger α-
syn pathology using immunofluorescent colabeling tech-
niques. Significant amounts of colocalization of α-syn
with Ras-related in brain 5 (Rab5), a small GTPase asso-
ciated with the biogenesis of multivesicular bodies [5],
occurred in DLB but not Ctl-injected brain slices
(Fig. 4a, b). Additionally, brains administered with DLB
derived exosomes expressed significantly higher levels
of α-syn accumulation in MAP5+ cells in than Ctl,
implicating DLB exosomes were internalized in neurons
(Fig. 4c, d). Interestingly, α-syn clusters were present in
GFAP+ cells of DLB-injected brain tissue when compared
to Ctl (Fig. 4e, f ). Finally, colocalization of human and
mouse α-syn was exclusively detected in DLB injected
brain slices (Fig. 4g, h). Taken together, these data suggest
that exosomes harboring potentially pathogenic forms of
α-syn can be taken up by non-diseased neurons and pos-
sibly astrocytes to induce α-syn accumulation.
Exosome-mediated α-syn accumulation is mediated by
endocytosis
Rab5 plays a broad role in the early endocytic pathway;
one major process regulated by the small GTPase is
endocytosis [5]. Previous studies suggest exogenous α-syn
is endocytosed via Rab5, leading to the formation of LB
and neuronal cell death [48]. To determine if DLB derived
exosomes utilize endocytotic mechanisms, we implemented
a cell-based assay to assess α-syn aggregation. First, to
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verify exosome content, exosome fractions from Ctl and
DLB patients were characterized through Western Blot.
Exosome markers CD63 and 81 were detected in both frac-
tions and α-syn exclusively in the DLB fraction (Fig. 4a). In
addition, EM analysis detected α-syn within DLB exosomes
(Fig. 4b). A significant amount of α-syn particles were iden-
tified in B103 neuroblastomas incubated with DLB-derived
but not Ctl exosomes (Fig. 4c, d). To determine if endo-
cytosis regulated exosome internalization of α-syn, B103
neuroblastomas were incubated with either Ctl or DLB
exosomes prior to endosomal inhibition either through 4 °
C incubation or application of Dynasore. Dissociation of
the microtubule complex involved in endocytosis by 4 °C
incubation reduced the number of α-syn-positive particles
(Fig. 4c, d). Similarly, inhibition of clathrin-mediated endo-
cytosis through Dynasore diminished detection of α-syn-
positive clusters (Fig. 4c, d). Together, these data further
suggest that the internalization of exosomes originating
from DLB patients via endocytosis promotes the intracellu-
lar aggregation of α-syn.
Discussion
Aggregate prone proteins are present in the biofluids of pa-
tients with synucleinopathies diseases [18, 19, 23, 28, 46].
However, it is unclear how exosomes are involved in
transmitting synuclein pathology. Previously, CSF exo-
somes isolated from patients diagnosed with various synu-
cleinopathies induced oligomerization of soluble α-syn in
cell culture [47]. In this exploratory study, we demonstrate
that viable exosomes containing Aβ, tau and α-syn isolated
from patients clinically and pathologically diagnosed for
DLB (Table 1, Figs. 1 and 2) can initiate α-syn and tau ac-
cumulation in non-diseased rodent brains (Fig. 3). In
addition, human α-syn accumulation mediated by DLB
exosomes was internalized in both mature neurons and
astroglia (Fig. 4c-f). Finally, delivery of α-syn via exosomes
was mediated by endocytosis (Fig. 5). These data provide
additional insight to how exosomes can serve a vector for
α-syn internalization and possibly take part in α-syn
pathogenesis.
Exosomal α-syn is detected in various bodily fluids of
patients with Lewy Body disorders, yet the pathological
potential is poorly understood [51]. Interestingly, indi-
viduals with Parkinson’s Disorder (PD) exhibited a sig-
nificant decrease of total CSF α-syn and exosomes
compared to controls [46, 47]. Even lower levels of CSF
exosomes were detected in DLB patients compared to
other synucleinopathy patients [47]. In this study, we fur-
ther characterize the content of DLB derived exosomes
and detect Aβ and tau within the cargo (Fig. 2c, d). Previ-
ous studies have shown Aβ interacts with α-syn to induce
toxicity [34]. Although Aβ accumulation is not present in
DLB-injected brain tissue, Aβ could interfere with the
components involved in exosome biogenesis leading to
overall exosome reduction. Despite the overall decrease in
total exosomes, DLB CSF exosomes contained a greater
Fig. 2 Aggregate prone proteins associated with disease are present in exosome cargo. a Representative micrographs of Ctl, AD and DLB brain
tissue, immunohistochemically stained for α-synuclein (α-syn), Amyloid Beta (Aβ) and phosphorylated tau (p-Tau). Scale bar for: α-syn = 5 μm,
Aβ = 10 μm and p-Tau = 5 μm. b-d Western blots detecting the presence of α-syn (b), Aβ-protein (c) and p-Tau (d) contained within each fraction
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amount of α-syn per exosome compared to PD CSF exo-
somes and incited α-syn aggregation [47]. We observed
intracellular accumulation of phosphorylated α-syn and
tau upon administration of DLB brain derived exosomes
to healthy rodent brain tissue (Fig. 3d, e), providing add-
itional evidence that DLB-derived exosomes have patho-
genic potential. In addition, α-syn accumulation observed
around the soma was of human origin (Fig. 4g), further
suggesting DLB exosomes contained high levels of α-syn.
It is important to note that we extract exosomes from fro-
zen brain tissue via ultracentrifugation to enrich for brain-
derived exosomes (Fig. 1a, [40]). It is possible that the exo-
some population assessed in our study may not reflect the
exosomal population in the CSF. Nevertheless, under-
standing the properties of DLB exosomes could shed
light into α-syn pathology. Furthermore, characterizing
brain-derived exosomes may provide further information
to distinguish central nervous system-derived exosomal
populations in bodily fluids.
Greater than 90% of LBs in patients with synucleino-
pathies contain α-syn phosphorylated at serine residue
129 (pSer129 α-syn) [38]. Furthermore, pSer129 α-syn is
associated with dementia as higher levels are present in
DLB than in PD [49]. Therefore, detecting pSer129 α-syn
would provide insight into the pathogenicity of α-syn har-
bored in DLB exosomes. Indeed, prominent LBs were
present in DLB patient tissues (Table 1, Fig. 2a). Import-
antly, a significant amount of pSer129 α-syn staining was
quantified in DLB-injected brain tissue (Fig. 3d-e), imply-
ing that exosomes extracted from DLB brain tissue con-
tained pSer129 α-syn. However, phosphorylation of
human α-syn is thought to occur after LB formation, as
pSer129 α-syn accumulation in LBs is detectable only in
the late stages of DLB progression [52, 54]. Further
Fig. 3 Administration of DLB exosomes into mouse brains initiates intracellular accumulation of phosphorylated proteins. a Representative EM
micrographs of exosomes from Ctl and DLB brain samples immunolabeled for α-syn. b Schematic of stereotaxic injection into the hippocampus
of C57BL/6 N × DBA/2 F1 mice. c Representative brightfield micrographs from mouse brains injected with control or DLB exosomes. Row 1:
Sagittal view of the hippocampal area. Needle entry site is highlighted by arrowhead. Boxes highlight region of interest depicted in micrographs
below. Scale bar = 150 μm. Rows 2–3: High magnification view of highlighted areas. Arrowheads highlight immunolabeled cell bodies.
Scale bar = 25 μm. d Micrographs of brain tissue stained with phosphorylated α-syn (pSer129), PHF1 and Aβ (6E10). Scale bar = 25 μm.
e Quantification of immunohistochemical stains from (c) and (d) through optical density. * = P < 0.05. Error bars indicate SEM
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characterization of the exosomal cargo for possible α-syn
variants may further elucidate the toxicity of DLB exosomes
as well as the role of pSer129 α-syn in LB formation.
Studies with synthetic α-syn proteins reported less aggre-
gation between human α-syn and endogenous α-syn in ro-
dent brains [33]. Although DLB exosomes contained α-syn
(Figs. 3a and 5b), it was unknown at the time if the amount
inside DLB exosomes would be sufficient for immunohisto-
logical detection. Aware of this caveat, we harvested the
DLB and Ctl-injected brains at 4 weeks. Indeed, we
detected expression of human α-syn in DLB-injected tissue
with punctate colocalization with mouse α-syn (Fig. 4g, h).
These data suggest the possibility of mouse and human α-
syn interactions in the terminals, where α-syn typically re-
sides in neurons [6]. Longer time points would address
whether this particular expression pattern of human
α-syn persists and if human α-syn is targeted by the
lysosomal pathway.
Translocation of extracellular oligomeric α-syn often
occurs through endocytosis [29], although it is not clear
Fig. 5 Inhibition of endocytosis inhibits exosomes-mediated α-syn accumulation. a Immunoblot and b electron microscopy confirm the presence
of α-syn containing exosomes from DLB patient. Scale bar = 50 nm. c B103 neuronal cell lines incubated with either Ctl or DLB exosomes and
were left alone (first row, Baseline), incubated in 4 °C (second row) or incubated with Dynasore (third row). Accumulation of α-syn was visualized
using the Syn1 antibody. Detail column indicates the region of interest magnified. d Quantification of α-syn positive particles in 37 °C (baseline),
incubation at 4 °C and at 37 °C with Dynasore. * = P < 0.05 (DLB compared to Ctl). Error bars indicate SEM
Fig. 4 Human α-syn internalization occurs in neurons and astrocytes. Representative immunofluoresent micrographs of mouse hippocampal brain
slices injected with either Ctl or DLB exosomes, depicting human α-syn (Green), DAPI (Blue) and a Rab5, c MAP2, e GFAP or g mouse α-syn (Red).
Scale bar = 25 μm. Percent colocalization of α-syn and b Rab5, d MAP2, f GFAP and h mouse α-syn. * = P < 0.05. Error bars indicate SEM
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how α-syn triggers uptake. Another way exosomes could
optimize α-syn internalization and therefore aggregation
is by activating endocytic pathways. Indeed, sonicating
exosomes disrupted α-syn internalization, suggesting that
exosomes need to be intact to efficiently shuttle α-syn into
the cell [11]. In addition, internalization of exosomes was
reduced with the digestion of exosome surface proteins by
proteases and inhibited at 4 °C [16]. This suggests that an
energy dependent process such as endocytosis mediates
exosome uptake. In our studies, DLB-mediated α-syn ac-
cumulation was abolished with the inhibition of endocyto-
sis (Fig. 5). Furthermore, human α-syn highly colocalized
with Rab5 in DLB exosome injected mouse brains (Fig. 4a,
b). These data suggest that α-syn contained in DLB exo-
somes is internalized through Rab5-mediated endocytosis.
In our studies, we observed 60% DLB-derived α-syn
colocalization with MAP2+ cells as opposed to about 2%
colocalization of α-syn observed in GFAP+ cells (Fig. 4c-
f ), implying DLB exosomes express preference for neu-
rons. Extended analysis of DLB exosome internalization
in non-neuronal cells such as oligodendocyte cell lines
would assess if DLB exosomes specifcially target neu-
rons. In addition, further characterization of the subtype
of the afflicted neurons would provide additional details
into the pathophysiology of DLB, which may hold diag-
nostic relevance in discerning DLB from PD.
Conclusions
Exosomes are an attractive biomarker that could pos-
sibly be used to diagnose neurodegenerative diseases.
Utilizing immunohistochemistry and Western blot ana-
lysis we observed that brain tissue originating from indi-
viduals diagnosed for AD or DLB (Table 1) and verified
to contain α-syn, Aβ and p-Tau aggregates (Fig. 2a), pro-
duced exosomes containing elevated levels of these
aggregate-prone proteins (Fig. 2a-d). In addition, our
current study demonstrates that exosomes can mediate
the internalization of exogenous α-syn into naïve neuronal
cells through endocytosis. These data imply exosomes
may play a role in α-syn pathogenesis, possibly through
the seeding of toxic forms of α-syn. Possible future studies
include researching how exosomes regulate α-syn trans-
mission based on cell subtype, which could have implica-
tions in diagnosing Lewy Body disorders.
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